Institution
Hebron University
Education•Hebron, Palestinian Territory•
About: Hebron University is a education organization based out in Hebron, Palestinian Territory. It is known for research contribution in the topics: Population & Cancer. The organization has 2714 authors who have published 4180 publications receiving 163736 citations.
Topics: Population, Cancer, Breast cancer, Medicine, Metastatic breast cancer
Papers published on a yearly basis
Papers
More filters
TL;DR: Predictive value of the sFlt-1 : PlGF Ratio in women with suspected Preeclampsia as discussed by the authors, which is the most commonly used ratio in the literature.
Abstract: Predictive Value of the sFlt-1 : PlGF Ratio in Women With Suspected Preeclampsia EDITORIAL COMMENT
624 citations
University of California, Los Angeles1, Memorial Sloan Kettering Cancer Center2, Columbia University Medical Center3, Princess Margaret Cancer Centre4, Samsung Medical Center5, Yale University6, University of Pennsylvania7, Vanderbilt University8, University of California, San Francisco9, Emory University10, Hebron University11, Merck & Co.12, University of Sydney13
TL;DR: Pembrolizumab monotherapy provided durable antitumor activity and high 5-year OS rates in patients with treatment-naive or previously treated advanced NSCLC and had a tolerable long-term safety profile with little evidence of late-onset or new toxicity.
Abstract: PURPOSEPembrolizumab monotherapy has demonstrated durable antitumor activity in advanced programmed death ligand 1 (PD-L1)–expressing non‒small-cell lung cancer (NSCLC). We report 5-year outcomes f...
618 citations
TL;DR: Everolimus significantly increased letrozole efficacy in neoadjuvant therapy of patients with ER-positive breast cancer and the safety profile was consistent with historical results of everolimus monotherapy.
Abstract: Purpose Cross-talk between the estrogen receptor (ER) and the phosphoinositide-3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) pathways is a mechanism of resistance to endocrine therapy, and blockade of both pathways enhances antitumor activity in preclinical models. This study explored whether sensitivity to letrozole was enhanced with the oral mTOR inhibitor, everolimus (RAD001). Patients and Methods Two hundred seventy postmenopausal women with operable ER-positive breast cancer were randomly assigned to receive 4 months of neoadjuvant treatment with letrozole (2.5 mg/day) and either everolimus (10 mg/day) or placebo. The primary end point was clinical response by palpation. Mandatory biopsies were obtained at baseline and after 2 weeks of treatment (ie, day 15). Samples were assessed for PI3K mutation status (PIK3CA) and for pharmacodynamic changes of Ki67, phospho-S6, cyclin D1, and progesterone receptor (PgR) by immunohistochemistry. Results Response rate by clinical palpation in the everol...
615 citations
TL;DR: Evidence is presented that the region harboring this variant is a transcriptional enhancer, that the alleles of rs6983267 differentially bind transcription factor 7-like 2 (TCF7L2) and that the risk region physically interacts with the MYC proto-oncogene.
Abstract: An inherited variant on chromosome 8q24, rs6983267, is significantly associated with cancer pathogenesis. We present evidence that the region harboring this variant is a transcriptional enhancer, that the alleles of rs6983267 differentially bind transcription factor 7-like 2 (TCF7L2) and that the risk region physically interacts with the MYC proto-oncogene. These data provide strong support for a biological mechanism underlying this non-protein-coding risk variant.
614 citations
TL;DR: Safety, pharmacokinetics, RNAi mechanism of action, and clinical activity with a novel LNP-formulated RNAi therapeutic in patients with cancer are shown, providing proof-of-concept for RNAi therapeutics in humans and the basis for further development in cancer.
Abstract: RNA interference (RNAi) is a potent and specific mechanism for regulating gene expression. Harnessing RNAi to silence genes involved in disease holds promise for the development of a new class of therapeutics. Delivery is key to realizing the potential of RNAi, and lipid nanoparticles (LNP) have proved effective in delivery of siRNAs to the liver and to tumors in animals. To examine the activity and safety of LNP-formulated siRNAs in humans, we initiated a trial of ALN-VSP, an LNP formulation of siRNAs targeting VEGF and kinesin spindle protein (KSP), in patients with cancer. Here, we show detection of drug in tumor biopsies, siRNA-mediated mRNA cleavage in the liver, pharmacodynamics suggestive of target downregulation, and antitumor activity, including complete regression of liver metastases in endometrial cancer. In addition, we show that biweekly intravenous administration of ALN-VSP was safe and well tolerated. These data provide proof-of-concept for RNAi therapeutics in humans and form the basis for further development in cancer. Significance: The findings in this report show safety, pharmacokinetics, RNAi mechanism of action, and clinical activity with a novel first-in-class LNP-formulated RNAi therapeutic in patients with cancer. The ability to harness RNAi to facilitate specific multitargeting, as well as increase the number of druggable targets, has important implications for future drug development in oncology. Cancer Discov; 3(4); 406–17. ©2012 AACR. This article is highlighted in the In This Issue feature, p. 363
611 citations
Authors
Showing all 2723 results
| Name | H-index | Papers | Citations |
|---|---|---|---|
| José Baselga | 156 | 707 | 122498 |
| M. I. Martínez | 134 | 1251 | 79885 |
| Josep Tabernero | 111 | 803 | 68982 |
| Jordi Rello | 103 | 694 | 35994 |
| Xavier Montalban | 95 | 762 | 52842 |
| James M. Downey | 91 | 381 | 29506 |
| Enriqueta Felip | 83 | 622 | 53364 |
| Joaquim Bellmunt | 82 | 660 | 41472 |
| Joan Montaner | 80 | 489 | 22413 |
| Marc Miravitlles | 76 | 651 | 25671 |
| David H. Salat | 75 | 241 | 36779 |
| Eduard Gratacós | 75 | 531 | 20178 |
| Alex Rovira | 74 | 356 | 19586 |
| Ramon Bataller | 72 | 283 | 19316 |
| Maria Buti | 71 | 493 | 26596 |